TriSalus Life Sciences, Inc. 8-K

What Happened
TriSalus Life Sciences, Inc. filed an 8-K reporting the results of its Annual Meeting of Stockholders held on May 14, 2026. A total of 41,728,676 shares (67.9% of outstanding common stock) were represented. The company elected two director nominees for three-year terms, ratified Grant Thornton LLP as its independent registered public accounting firm for fiscal 2026, and approved advisory votes on executive compensation and vote frequency.

Key Details

• Shares represented: 41,728,676 (67.9% of outstanding common stock).
• Directors elected (terms expiring 2029):
  • Mary Szela — For: 31,393,310; Withhold: 2,614,246; Broker non-votes: 7,721,120.
  • Gary Gordon — For: 31,339,161; Withhold: 2,668,395; Broker non-votes: 7,721,120.
• Auditor ratification: Grant Thornton, LLP — For: 41,098,385; Against: 28,667; Abstain: 601,624.
• Advisory votes on executive pay:
  • Frequency vote (advisory): 3 years received the most support — 3-year votes: 20,348,386 (Board adopted a three-year frequency).
  • Say-on-pay (advisory): For: 32,625,082; Against: 1,206,105; Abstain: 176,369.
• Report signed by David Patience, Chief Financial Officer, dated May 14, 2026.

Why It Matters
The results indicate shareholder support for the company’s current board slate and executive compensation approach, and preserve continuity by retaining Grant Thornton as auditor. The Board’s decision to hold advisory votes on pay every three years (consistent with the plurality outcome) reduces the frequency of future say-on-pay votes. For investors, these outcomes suggest governance stability and no immediate changes to leadership, audit oversight, or executive pay policy arising directly from this meeting.